uniQure N.V. (QURE) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sarepta Therapeutics (SRPT) has outperformed uniQure N.V. (QURE) over the past year, losing 24.6% versus a loss of 30.4%. Over five years, QURE leads with a -32.9% price change compared with -83.3% for SRPT. Sarepta Therapeutics is the larger company by market cap ($1.43 billion vs $1.36 billion), about 1.1 times the size.
Sarepta Therapeutics converts more of its revenue into profit, with a net margin of -32.5% versus -1236.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | SRPT |
|---|---|---|
| Share price | $19.35 | $13.33 |
| Market cap | $1.36B | $1.43B |
| 1-day change | -4.35% | -5.93% |
| YTD return | -19.14% | -38.06% |
| 1-year return | -30.42% | -24.65% |
| 5-year return | -32.86% | -83.26% |
| P/E ratio (TTM) | — | 666.50 |
| Forward P/E | — | 8.87 |
| EPS (TTM) | $-3.51 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $16.10M | $2.20B |
| Revenue growth (YoY) | -40.64% | +15.58% |
| Net income (latest FY) | $-198.97M | $-713.41M |
| Gross margin | 89.53% | 98.84% |
| Operating margin | -1151.38% | -31.83% |
| Net margin | -1236.00% | -32.45% |
| 52-week high | $51.72 | $24.68 |
| 52-week low | $8.73 | $13.25 |
| Distance from 52-week high | -62.59% | -45.99% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +207.03% | +63.32% |
| Average volume | 2.26M | 2.70M |
| Shares outstanding | 70.14M | 107.24M |
| Employees | 221 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sarepta Therapeutics is more profitable, keeping -32.5 cents of every revenue dollar as net income versus -1236.0 cents for uniQure N.V..
- Sarepta Therapeutics grew revenue faster in its latest fiscal year (+15.58% vs -40.64%).
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
QURE vs SRPT FAQ
Which is bigger, uniQure N.V. or Sarepta Therapeutics?
Sarepta Therapeutics (SRPT) is larger, with a market capitalization of $1.43B compared with $1.36B for uniQure N.V. (QURE).
Which stock has performed better over the past year, QURE or SRPT?
SRPT returned -24.65% over the past 12 months, compared with -30.42% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.